Compare Novo Nordisk A/S (NVO) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Short Term Corporate Bond ETF — how do they compare? Novo Nordisk A/S trades at $45.1 (market cap $200.69B), while Vanguard Short Term Corporate Bond ETF trades at $78.09. The key difference: Novo Nordisk A/S pays a 3.98% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | VCSH | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $80.20 |
52-Week Low | $35.29 | $78.08 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $78.14 with minimal daily movement (-0.05%). The technical picture is bearish with moving averages signaling caution, though oversold RSI readings suggest potential near-term support. The ETF maintains a competitive 4.5% dividend yield with a short 2.7-year duration, positioning it defensively against rising rates while offering higher income than treasury alternatives.
While VCSH provides quality short-term corporate bond exposure with minimal interest rate risk, current tight credit spreads limit upside potential. The ETF faces competition from broader bond funds and carries corporate credit risk. Recent analyst downgrades to 'Hold' reflect concerns about entry timing, though institutional investors continue active positioning in the fund.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
